Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pelthos Therapeutics (PTHS) EBITDA (2024 - 2025)

Pelthos Therapeutics has reported EBITDA over the past 2 years, most recently at -$12.0 million for Q4 2025.

  • Quarterly results put EBITDA at -$12.0 million for Q4 2025, down 558.06% from a year ago — trailing twelve months through Dec 2025 was -$32.4 million (down 328.33% YoY), and the annual figure for FY2025 was -$43.3 million, down 444.55%.
  • EBITDA for Q4 2025 was -$12.0 million at Pelthos Therapeutics, up from -$15.4 million in the prior quarter.
  • Over the last five years, EBITDA for PTHS hit a ceiling of -$1.8 million in Q2 2024 and a floor of -$15.4 million in Q3 2025.